Table 4.

HRs in the triple-negative group compared with the other group

End pointUnadjusted
Adjusted
HR (95% CI)PHR (95% CI)P
Risk of local recurrence
    Entire follow-up period1.1 (0.7-1.7)0.600.8 (0.5-1.3)0.38
    0 to 5 y follow-up1.5 (1.0-2.5)0.081.0 (0.6-1.7)0.98
    5 y to end of follow-up0.4 (0.1-1.3)0.10.3 (0.1-1.1)0.08
Risk of distant recurrence
    Entire follow-up period1.9 (1.4-2.5)<0.00011.2 (0.9-1.5)0.35
    0 to 5 y follow-up2.6 (2.0-3.5)<0.00011.5 (1.1-2.0)0.02
    5 y to end of follow-up0.5 (0.2-1.1)0.090.3 (0.1-0.8)0.02
Risk of death
    Entire follow-up period1.7 (1.3-2.2)<0.00011.3 (1.0-1.6)0.09
    0 to 5 y follow-up2.6 (1.9-3.6)<0.00011.7 (1.3-2.4)0.0007
    5 y to end of follow-up1.0 (0.6-1.5)<0.80.7 (0.5-1.2)0.22
Death due to breast cancer
    Entire follow-up period2.1 (1.6-2.8)<0.00011.3 (1.0-1.7)0.08
    0 to 5 y follow-up3.2 (2.3-4.5)<0.00011.8 (1.3-2.6)0.0005
    5 y to end of follow-up1.0 (0.6-1.7)1.00.7 (0.4-1.1)0.1
  • NOTE: A Cox model, including age at diagnosis, grade (1, 2, 3), nodal status (negative, positive), tumor size (T1, T2, T3), chemotherapy (yes, no), and tamoxifen therapy (yes, no), was used to estimate the adjusted HRs. P values were determined by the log-rank test.